Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997–2010: A Danish cohort study

2014 ◽  
Vol 25 (8) ◽  
pp. 731-738 ◽  
Author(s):  
Anne Gjesing ◽  
Gunnar H. Gislason ◽  
Lars Køber ◽  
J. Gustav Smith ◽  
Stefan Bisgaard Christensen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Cohort Study ◽  
Danish Cohort ◽  
First Time

scholarly journals Heart failure associated with imported malaria: a nationwide Danish cohort study

2021 ◽  
Author(s):  
Philip Brainin ◽  
Grimur Høgnason Mohr ◽  
Daniel Modin ◽  
Brian Claggett ◽  
Odilson M. Silvestre ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cohort Study ◽  
Imported Malaria ◽  
Danish Cohort

scholarly journals Comorbidity and risk of venous thromboembolism after hospitalization for first‐time myocardial infarction: A population‐based cohort study

2020 ◽  
Vol 18 (8) ◽  
pp. 1974-1985
Author(s):  
Morten Würtz ◽  
Erik Lerkevang Grove ◽  
Priscila Corraini ◽  
Kasper Adelborg ◽  
Jens Sundbøll ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Population Based ◽  
First Time

Recent temporal trends for first-time hospitalization for acute myocardial infarction. Treatment patterns and clinical outcome in a large cohort study

2013 ◽  
Vol 166 (5) ◽  
pp. 846-854 ◽  
Author(s):  
Paolo Ortolani ◽  
Massimiliano Marino ◽  
Giovanni Melandri ◽  
Paolo Guastaroba ◽  
Alessandro Corzani ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cohort Study ◽  
Clinical Outcome ◽  
Temporal Trends ◽  
Treatment Patterns ◽  
Large Cohort ◽  
Large Cohort Study ◽  
First Time

scholarly journals Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study

BMJ ◽  
2015 ◽  
Vol 350 (feb05 19) ◽  
pp. h411-h411 ◽  
Author(s):  
K. Dharmarajan ◽  
A. F. Hsieh ◽  
V. T. Kulkarni ◽  
Z. Lin ◽  
J. S. Ross ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort

scholarly journals Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Shih-Chieh Shao ◽  
Kai-Cheng Chang ◽  
Ming-Jui Hung ◽  
Ning-I Yang ◽  
Yuk-Ying Chan ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Cohort Study ◽  
Ischemic Stroke ◽  
Cardiovascular Events ◽  
Cardiovascular Death ◽  
Sglt2 Inhibitors ◽  
Diabetes Patients

Abstract Background To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin. Methods We conducted a retrospective cohort study by analyzing a multi-institutional electronic medical records database (Chang Gung Research Database) in Taiwan and included adult type 2 diabetes patients who were newly receiving sodium–glucose co-transporter 2 (SGLT2) inhibitors from 2016 to 2017. The primary outcome was a composite of cardiovascular death, myocardial infarction, ischemic stroke and heart failure. We followed up patients from initiation of SGLT2 inhibitors until the occurrence of cardiovascular events before December 31, 2018. We performed multivariable Cox proportional hazard modeling, adjusting for patients’ age, sex, laboratory data, co-morbidities, and concomitant medications. Results We identified 12,681 new SGLT2 inhibitor users with a mean age of 58.9 (SD 11.8) years, of whom 43.9% were female and 45.8% were new dapagliflozin users. A total of 10,442 person-years of dapagliflozin use and 12,096 person-years of empagliflozin use were included. Compared to empagliflozin users, new users of dapagliflozin were found to have similar risks for primary composite outcome (adjusted HR: 0.91; 95% CI 0.73–1.14), cardiovascular death (adjusted HR: 0.54; 95% CI 0.14–2.12), myocardial infarction (adjusted HR: 0.77, 95% CI 0.49–1.19) and ischemic stroke (adjusted HR: 1.15; 95% CI 0.80–1.65), but a lower risk of heart failure (adjusted HR: 0.68; 95% CI 0.49–0.95). Conclusion The risk of cardiovascular events was similar between dapagliflozin and empagliflozin new users, but dapagliflozin may have a better outcome in the reduction of heart failure in type 2 diabetes patients. Future prospective studies are required to confirm the findings.

Sign in / Sign up

Export Citation Format

Share Document